Doi Hirokazu, Sakakibara Ryuji, Sato Mitsutoshi, Hirai Shigekazu, Masaka Tohru, Kishi Masahiko, Tsuyusaki Yohei, Tateno Akihiko, Tateno Fuyuki, Takahashi Osamu, Ogata Tsuyoshi
Pharmaceutical Unit, Sakura Medical Center, Toho University, Sakura, Japan.
Mov Disord. 2014 Apr;29(4):562-6. doi: 10.1002/mds.25777. Epub 2013 Dec 27.
The objective of this work was to perform an open trial of the effects of nizatidine (NZT), a selective histamine H2-receptor antagonist and a cholinomimetic, on gastroparesis in Parkinson's disease (PD) patients, using objective parameters given by a gastric emptying study using a (13) C-sodium acetate expiration breath test.
Twenty patients with PD were enrolled in the study. There were 13 men and 7 women; aged 68.0 ± 7.72 years; disease duration 5.50 ± 3.62 years. All patients underwent the breath test and a gastrointestinal questionnaire before and after 3 months of administration of NZT at 300 mg/day. Statistical analysis was performed by Student t test.
NZT was well tolerated by all patients and none had abdominal pain or other adverse effects. NZT significantly shortened Tmax ((13) C) (the peak time of the (13) C-dose-excess curve) (P < 0.05).
Although this is a pilot study, we found a significant shortening of gastric emptying time after administration of NZT in PD patients.
本研究旨在利用（13）C-醋酸钠呼气试验进行胃排空研究给出的客观参数，对帕金森病（PD）患者开展一项关于尼扎替丁（NZT，一种选择性组胺H2受体拮抗剂及拟胆碱药）对胃轻瘫影响的开放性试验。
20例PD患者纳入本研究。其中男性13例，女性7例；年龄68.0±7.72岁；病程5.50±3.62年。所有患者在每天服用300mg NZT 3个月前后均接受呼气试验及一份胃肠道问卷。采用学生t检验进行统计学分析。
所有患者对NZT耐受性良好，均未出现腹痛或其他不良反应。NZT显著缩短了Tmax（（13）C）（（13）C剂量过量曲线的峰值时间）（P<0.05）。
尽管这是一项初步研究，但我们发现PD患者服用NZT后胃排空时间显著缩短。
